Holmusk’s mission is to transform the lives of people with behavioral health issues and chronic diseases through data driven medicine. Specifically, the Company aims to create the largest real world evidence (RWE) platform in the fields of behavioral health and neuroscience, to improve care for patients and fuel innovation among pharma companies. The Company’s proprietary technology is also harnessed to analyze real-world data across chronic metabolic diseases including diabetes, cardiovascular disease, and similar degenerative conditions.
Holmusk believes that an integrated care model incorporating data concerning mental health and other chronic conditions will make access to RWE a reality of today rather than a dream of tomorrow.
In April 2020, Health Catalyst Capital made a convertible preferred equity investment in Holmusk and currently is represented on the board of directors of the Company. We look forward to working collaboratively with senior management to help the Company execute its strategy.